TY - JOUR
T1 - Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib
T2 - A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG)
AU - Glabbeke, Martine Van
AU - Verweij, Jaap
AU - Casali, Paolo G.
AU - Simes, John
AU - Cesne, Axel Le
AU - Reichardt, Peter
AU - Issels, Rolf
AU - Judson, Ian R.
AU - van Oosterom, Allan T.
AU - Blay, Jean Yves
N1 - Funding Information:
This publication was supported by grant(s) number 2U10 CA11488-29 (through 5U10 CA11488-34) from the National Cancer Institute (Bethesda, Maryland, United States of America (USA)). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.
Funding Information:
J. Verweij, P. Casali, P. Reichard, A. van Oosterom, I. Judson and JY Blay have received research grants, travel support or/and honoraria for speaking engagements and as members of various Novartis advisory boards. The EORTC–IST–AGITG study was funded by an unrestricted grant from Novartis Oncology. However, the study was conducted independently under the supervision of the steering committee. Novartis was not involved in study design, data collection or data analysis.
PY - 2006/9/1
Y1 - 2006/9/1
N2 - The aim of this study was to identify prognostic factors for toxicity to treatment with imatinib. The study was based on 942 patients with gastrointestinal stromal tumours (GIST) randomised to receive imatinib at different doses. The correlation between toxicities occurring with a Common Toxicity Criteria (CTC) grade 2 or more (non-haematological) or grade 3 or 4 (haematological) and imatinib dose, age, sex, performance status, original disease site, site and size of lesions at trial entry, baseline haematological and biological parameters was investigated. Anaemia was correlated with dose and baseline haemoglobin level, and neutropaenia with baseline neutrophil count and haemoglobin level. The risk of non-haematological toxicities was dose dependent and higher in females (oedema, nausea, diarrhoea), and in patients of advanced age (oedema, rash fatigue), poor performance status (fatigue and nausea), prior chemotherapy (fatigue), tumour of identified gastrointestinal origin (diarrhoea) and small lesions (rash). A multivariate risk calculator that can be used in the clinic for individual patients is proposed.
AB - The aim of this study was to identify prognostic factors for toxicity to treatment with imatinib. The study was based on 942 patients with gastrointestinal stromal tumours (GIST) randomised to receive imatinib at different doses. The correlation between toxicities occurring with a Common Toxicity Criteria (CTC) grade 2 or more (non-haematological) or grade 3 or 4 (haematological) and imatinib dose, age, sex, performance status, original disease site, site and size of lesions at trial entry, baseline haematological and biological parameters was investigated. Anaemia was correlated with dose and baseline haemoglobin level, and neutropaenia with baseline neutrophil count and haemoglobin level. The risk of non-haematological toxicities was dose dependent and higher in females (oedema, nausea, diarrhoea), and in patients of advanced age (oedema, rash fatigue), poor performance status (fatigue and nausea), prior chemotherapy (fatigue), tumour of identified gastrointestinal origin (diarrhoea) and small lesions (rash). A multivariate risk calculator that can be used in the clinic for individual patients is proposed.
KW - GIST
KW - Imatinib
KW - Prognostic factors
KW - Toxicities
UR - http://www.scopus.com/inward/record.url?scp=33748262260&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2006.03.029
DO - 10.1016/j.ejca.2006.03.029
M3 - Article
C2 - 16876399
AN - SCOPUS:33748262260
SN - 0959-8049
VL - 42
SP - 2277
EP - 2285
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 14
ER -